New Episode Highlights the Painful, Often Misunderstood Reality of Living with Netherton Syndrome and the Urgent Need for Effective TreatmentsASHBURN, Va., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the release of the fourth episode in its NETHERTON NOW video series. This installment features Mandy Aldwin-Easton, a Netherton Syndrome patient ...

- Positive 6 Month Clinical Data Reported for Ongoing Pediatric Netherton Syndrome Study - FDA Clears Second Pivotal Study of QRX003 for Netherton Syndrome - Initial Positive Data Announced from Peeling Skin Syndrome Pediatric Study - Orphan Drug Designation Granted by European Medicines Agency for QRX003 - Rare Pediatric Disease Designation Awarded by U.S. FDA - NETHERTON NOW Campaign Expanded with New Patient and Expert Video Releases ASHBURN, Va., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals L ...

Core Insights - Quoin Pharmaceuticals has released a new episode in its NETHERTON NOW video series, highlighting the severe burden of Netherton Syndrome in infants and children and the need for effective pediatric treatments [1][4] - The U.S. FDA has granted Rare Pediatric Disease Designation for Quoin's lead product candidate, QRX003, which aims to address the serious and underserved nature of Netherton Syndrome in pediatric patients [3][4] Company Overview - Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, with a commitment to addressing unmet medical needs [6] - The company is developing a pipeline of four products targeting various rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, and others [6] Product Information - QRX003 is a topical lotion designed to promote a normalized skin-shedding process and strengthen the skin barrier in patients with Netherton Syndrome [5] - The mechanism of action for QRX003 involves a proprietary delivery technology that contains a broad-spectrum serine protease inhibitor, which mimics the function of a specific protein called LEKTI [5] Expert Insights - Professor Jemima Mellerio, a recognized authority in dermatology, emphasizes the life-threatening challenges of Netherton Syndrome and the critical need for improved therapeutic options [2][3] - The experiences shared by Professor Mellerio in the NETHERTON NOW series highlight the challenges faced by children and families living with this condition [4]

Core Viewpoint - Quoin Pharmaceuticals has received Rare Pediatric Disease Designation from the FDA for its lead asset QRX003, aimed at treating Netherton Syndrome, a rare genetic disorder affecting children [1][3][4] Company Overview - Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing treatments for rare and orphan diseases, with a pipeline that includes four products targeting various conditions [5] Regulatory Designations - The FDA's Rare Pediatric Disease Designation for QRX003 highlights its potential as a therapeutic candidate for an underserved pediatric population, following the Orphan Drug Designation granted by the EMA in May 2025 [2][3] Clinical Development - The company is focused on completing pivotal clinical studies for QRX003 and advancing it towards a New Drug Application (NDA) as the first potential treatment for Netherton Syndrome [3][5] Disease Background - Netherton Syndrome is a rare genetic disorder affecting approximately 1 in 200,000 newborns, with symptoms that can lead to severe skin inflammation and a mortality rate in infancy estimated at 10 to 20 percent [4]